Lebrikizumab for face and neck eczema in teens and adults
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injected medicine, lebrikizumab, for people whose eczema mainly affects the face and neck. It aims to see if it can improve these hard-to-treat areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and weigh at least 40 kg (about 88 pounds).
- You must have had eczema for at least one year and it must be moderate or severe, especially on your face and neck.
- You must also have eczema patches on other parts of your body, not just the face and neck.
- You cannot have used lebrikizumab before, and you can have only tried one of certain other eczema treatments (like Dupixent or a JAK inhibitor).
- You must not have other skin conditions on the face or neck that might confuse the results, like rosacea or seborrheic dermatitis.
- You cannot be pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests how well lebrikizumab (Ebglyss), an approved treatment for moderate-to-severe atopic dermatitis (eczema), works in everyday clinical practice. It aims to see how the drug affects your symptoms and quality of life over time, helping guide better treatment decisions.
This study looks at how lebrikizumab, a biologic medicine for atopic dermatitis (eczema), affects the skin's microbiome (the natural community of microorganisms on your skin). It aims to see if changes in the skin's microbiome are linked to treatment response.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.